2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
Iyer S, Sica R, Ho P, Prica A, Zain J, Foss F, Hu B, Beitinjaneh A, Weng W, Kim Y, Khodadoust M, Huen A, Williams L, Ma A, Huang E, Ganpule A, Nagar S, Sripakdeevong P, Cullingford E, Karnik S, Dequeant M, Patel J, He X, Li Z, He Q, Mendonez J, Keegan A, Horwitz S. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. The Lancet Oncology 2024 PMID: 39617017, DOI: 10.1016/s1470-2045(24)00508-4.Peer-Reviewed Original ResearchT-cell lymphomaPeripheral T-cell lymphomaCutaneous T-cell lymphomaRefractory T-cell lymphomaEastern Cooperative Oncology GroupChimeric antigen receptorCytokine release syndromeCAR+ T cellsSerious adverse eventsAdverse eventsT cellsOpen-labelRefractory peripheral T-cell lymphomaAllogeneic chimeric antigen receptorHealthy donor T cellsRefractory T-cell malignanciesCAR-T cell therapyMedian patient follow-upIncidence of adverse eventsDonor T cellsObjective response rateSystemic therapy linesDose-limiting toxicityT-cell therapyDose-escalation study
2022
Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
Zain, Iyer S, Sica R, Ho P, Hu B, Prica A, Weng W, Kim Y, Khodadoust, Palomba M, Foss F, Tipton K, Cullingford E, Horwitz S, Sharma A, Horwitz S. Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies. European Journal Of Cancer 2022, 173: s21. DOI: 10.1016/s0959-8049(22)00591-3.Peer-Reviewed Original ResearchS262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES
Iyer S, Sica R, Ho P, Hu B, Zain J, Prica A, Weng W, Kim Y, Khodadoust M, Palomba M, Foss F, Tipton K, Cullingford E, He Q, Sharma A, Horwitz S. S262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES. HemaSphere 2022, 6: 163-164. DOI: 10.1097/01.hs9.0000843940.96598.e2.Peer-Reviewed Original Research